Ask AI
ProCE Banner Series

Implementing Systemic Therapy in H3 K27–Altered DMG: Practical Strategies to Optimize Postradiation Care

Recent innovation and FDA approval have given additional options of systemic therapy for diffuse midline glioma (DMG). In this activity, learners will examine high-level evidence on new therapeutics and consider how these principles apply to both adult and pediatric patient populations with DMG, along with the relevant molecular biology about H3 K27M.

SNO has reviewed and approved this symposium as appropriate for presentation as an Independent Supported Session. The session constitutes the content and views of the sponsor and is not part of the official 2026 SNO Annual Meeting program.

  AMA
Who Should Attend

This activity is intended for neuro-oncologists and other healthcare professionals who care for patients with diffuse midline glioma. 

All Events

Implementing Systemic Therapy in H3 K27–Altered DMG: Practical Strategies to Optimize Postradiation Care

Upcoming Events

November

13

2026

6:30 AM - 8:15 AM Eastern Time (ET)

In-person

7:00 AM - 8:15 AM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
The goal of this activity is to improve learners’ knowledge, competence, and confidence in managing patients with H3 K27M–mutated diffuse midline glioma.

Target Audience
This activity is intended for neuro-oncologists and other healthcare professionals who care for patients with diffuse midline glioma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply molecular testing pathways to confirm H3 K27 status and document eligibility decisions at diagnosis and progression

  • Interpret the latest efficacy, safety, and regulatory data supporting protease activator therapy in recurrent DMG following radiation to inform evidence-based care decisions

  • Implement a post-RT sequencing algorithm integrating symptoms, steroid trajectory, imaging interpretation, and trial referral ready monitoring workflow (QTc risk screening/monitoring, symptom triage, escalation thresholds) in pediatric and adult settings

  • Identify patients for biomarker-driven clinical trials investigating novel targeted therapies and combination strategies in DMG, including earlier-line settings where clinically appropriate

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine Maintenance of Certification

Title: A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191